DIRS.INFO The most relevant business & tech news

Meanwhile, Redburn Atlantic initiated coverage of DoorDash with a buy rating and a price target implying upside of more than 60%. He also notched down his price target to $29 from $32, indicating 9.4% downside potential from Thursday's close. Analyst Vivek Arya reiterated his buy rating on the Dutch-based chipmaker in a client note on Thursday. He also cut his price target to $1.25 from $6.25, which was 7 cents below Thursday's close price. DASH YTD mountain AAPL year to date — Hakyung Kim 5:33 a.m.: Raymond James raises Apple price target Raymond James is getting more bullish on Apple ahead of earnings.

Persons: Raymond James, Michael Linenberg, Linenberg, Southwest's, — Hakyung Kim, BofA, Vivek Arya, NXP, NXPI, Arya, Davidson, Alexander Perry's, Perry, Morgan Stanley, International Morgan Stanley, Nathan Feather, Feather, Hakyung Kim, James Cordwell, Cordwell, EBITDA, Srini Pajjuri, Fred Imbert Organizations: CNBC, Apple, Southwest Airlines Deutsche Bank, Southwest Airlines, Revenue, NXP, Bank of America, EV, Harley, International, WW International, DoorDash Locations: U.S, China, Thursday's, 2H24

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

☆ Which Weight Loss Drug Should You Choose (if You Get to Choose)?
▼ + stars: | 2024-07-19 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

People with obesity now have a choice between two powerful drugs to help them lose weight. One is semaglutide, sold by Novo Nordisk as Wegovy for obesity treatment and as Ozempic for diabetes. A recent study suggested that people lost more weight taking Mounjaro than they did taking Ozempic, and it may leave you wondering: Which should I take? Is one weight loss drug really better than the other? All of the information available comes from “highly flawed studies,” said Dr. Diana Thiara, medical director of the weight loss clinic at the University of California, San Francisco.

Persons: Eli Lilly, I’m, ”, Diana Thiara Organizations: Novo Nordisk, University of California Locations: San Francisco

Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Costco : While Costco gets nearly 7% of its sales from China, Jim said it's unlikely its business would be threatened by geopolitics given the company's popularity in the country. Constellation Brands : There's no doubt that the Modelo and Corona parent is a less attractive stock under Trump compared with Biden. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump, Abbott's, Reckitt Benckiser, we're, there's, it's, Biden, Dupont, Trump, Walt Disney, Nelson Peltz, Jim said, Estee Lauder, Eaton, Honeywell's, Washington that's, Eli Lilly, Roche, Eli Lilly's, Lilly, Sen, J.D, Vance of, Morgan Stanley, ChatGPT, chipmaker, Laxman Narasimhan, Stanley Black, Decker, rightsizing, Wells, Wynn, he's, Jim Cramer, Brendan McDermid Organizations: Jim Cramer's Charitable Trust, CNBC, Trump, Abbott Laboratories, AMD, Broadcom, VMWare, Costco, Coterra Energy, White, Bloomberg, Federal, Motors, Ford, GE Healthcare, Big Tech, Honeywell, Air Products, Linde, Meta, Microsoft, Investors, OpenAI, Republican, Palo Alto Networks, Palo, Procter & Gamble, Biden, Constellation Brands, Modelo, The, TJX, Wynn Resorts, Club, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: China, Dover, U.S, Washington, Vance of Ohio, Meta, Taiwan, Israel, Gaza, Corona, Wells Fargo, Macau, New York City

☆ Counterfeit Ozempic Is on the Rise
▼ + stars: | 2024-07-12 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

Experts have grown increasingly concerned about fake versions of Ozempic and popular weight loss drugs. These copycats can look deceptively real, and may contain dangerous substances or entirely different drugs altogether. In June, the World Health Organization warned that fake batches of Ozempic were found in the United States, the United Kingdom and Brazil. Also in June, Eli Lilly issued a letter expressing concern that counterfeit versions of its own drugs, Mounjaro and Zepbound, were being sold online, through social media and at medical spas. Those who study the counterfeit drug market say these findings are alarming, but not all that surprising.

Persons: Eli Lilly, ”, George Karavetsos Organizations: World Health Organization, Food, Drug, Criminal Investigations Locations: United States, United Kingdom, Brazil

☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Netflix, Meta, Tesla, Eli Lilly, Walmart, Microsoft, Oracle & more
▼ + stars: | 2024-07-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

TD Cowen reiterates Meta as buy TD Cowen raised its price target on Meta to $600 per share from $530. Bank of America downgrades Visa & Mastercard to neutral from buy Bank of America said it sees "limited upside" for the payment stocks. Bank of America downgrades WK Kellogg to underperform from neutral Bank of America said it sees weakening industry trends for WK Kellogg. "We're initiating coverage of Bausch + Lomb (BLCO) with an Outperform rating and $19 price target." Bank of America initiates Composecure as buy Bank of America said it's bullish on shares of the metal payment card manufacturer.

Persons: Bernstein, Iris, it's bullish, Argus, Teva, Piper Sandler downgrades, Piper, Jefferies, Redburn, Goldman Sachs, Tesla, Goldman, Eli Lilly, Morgan Stanley, Needham, BTIG, it's, TD Cowen, Meta, WK Kellogg, Cobra Kai, Truist, Nomura, Raymond James, Bausch Organizations: Iris Energy, Walmart, Fox Robotics, Spotify, Oracle, Barclays, Microsoft, Citi, Quest, Bank of America, MKS, Southwest Citi, Southwest Airlines, Amazon, YouTube, Meta, " Bank of America, Visa, Mastercard, of America, SNAP, Netflix, Apple, Nvidia Locations: Mounjaro, Alaska, Southwest, underperform

Goldman Sachs raised its price target on Tesla, but it still sees a a decline for the electric vehicle maker. Analyst Chris Pierce upgraded his rating to buy from hold and assigned a $160 price target on Carvana, implying shares could jump 27.3%. His $77 price target on Walmart suggests the stock could jump nearly 10.2% over the next 12 months. Analyst Peter Keith assumed coverage of the retailer with a neutral rating and $156 price target, suggesting shares can add 5.7% over the next year. LLY YTD mountain LLY year to date — Pia Singh 5:51 a.m.: Goldman raises Tesla price target, but still sees stock slide Don't expect Tesla's recent momentum to last, according to Goldman Sachs The bank raised its price target on the electric vehicle maker to $248 from $175.

Persons: Tesla, Goldman Sachs, Eli Lilly, Needham, Chris Pierce, Pierce, — Pia Singh, Jefferies, Corey Tarlowe, Tarlowe, Piper Sandler, Peter Keith, Keith, Carter Gould, Gould, Goldman, Mark Delaney, Fred Imbert Organizations: CNBC, Barclays, Jefferies, Walmart, Fox Robotics, EV, Tesla Locations: Tuesday's

☆ Here's why KeyBanc analysts see more than 40% upside for Nvidia stock
▼ + stars: | 2024-07-09 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. KeyBanc raised its price target on the Club chipmaker's stock to $180 per share from $130. New research indicated that tirzepatide, the active ingredient in Lilly's Mounjaro for diabetes and Zepbound for weight loss leads to more weight loss than Novo Nordisk's semaglutide. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Goldman Sachs, Piper Sandler, —, KeyBanc, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Apple, Big Tech, Nvidia, Club, Blackwell, Novo Nordisk's semaglutide

☆ Stocks making the biggest moves midday: Nvidia, Corning, Helen of Troy, UiPath and more
▼ + stars: | 2024-07-09 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Helen of Troy — The housewares stock plummeted nearly 28%, hitting a new 52-week low during the session. The company posted an earnings miss for its first quarter of fiscal 2025 before the bell, earning 99 cents per share, excluding items. Lucid — The electric vehicle company's stock added nearly 1% after rallying about 8% in the previous session. Lucid jumped after the firm said it delivered 2,394 vehicles in the second quarter, marking a 70% year-over-year increase. Tesla — Shares of the electric vehicle company popped more than 4%.

Persons: Blackwell, Helen of Troy —, FactSet, UiPath, Lucid, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Corning, Yun Li, Pia Singh, Sarah Min, Darla Mercado Organizations: Nvidia, UBS, BP — U.S, Novo Nordisk, Novo Nordisk's Ozempic, Sony, Paramount, National Amusements, Skydance Media, Apollo, CNBC Locations: Novo

“My cart looks ridiculous,” said Ms. Uhuru, 48, who supplements her hauls with vegetables grown in her garden. “People think I am a shift shopper.” Sylvia Jarrus for The New York Times, including previous image. Sawyer’s April Shopping Total shopping trips: 14 Impulse purchases: Castelvetrano olives ($5.99) and sparkling water (prices vary) Share of drinkable purchases: 70 percent What might a stranger notice if she peered into Sawyer Bonsib’s cart? “The old adage ‘Don’t go grocery shopping when you are hungry,’ applies triply during Ramadan,” he said. “Or my toddler will gnaw on a tortilla while I’m making dinner.” Jessica Attie for The New York Times, including previous image.

Persons: —, creamer, Jackie Kesterson, haven’t, ”, “, Kesterson, Rebecca Gratz, Kimberly Uhuru Detroit, Kimberly Uhuru, Uhuru, ” Sylvia Jarrus, Sawyer, Mr, Bonsib, Alcoholics Anonymous, isn’t, ” Will Newton, pita —, Pecorino Romano, pistachios, Ayse Gilbert, Gilbert, She’s, ” Kerry Tasker, Sonal Singh, Singh, Carolyn Fong, Bingahlan, Abdul Bingahlan, chiles, We’re, Bingahalan, ‘, Brittainy Newman, Amy O’Neill Houck, ” — Mindy Huskins, — Naeman Mahmood, ” — Martha Goff, Gabby Cavazos Austin, Gabby Cavazos, Cavazos, ” Jessica Attie, Young, Alan Young, . Young, Croix seltzer Organizations: THE, Amazon Grocery, Vee, The New York Times, Walmart, Alcoholics, Costco, Gilbert Anchorage, University of Georgia, Mart, chiles, Atlanta, Emory, Coordinating, Foods, Assistance, SNAP Locations: United States, romaine, Jackie Kesterson Omaha, Rosedale Park, Target, Croix, Waterloo, Malvern, Ark, Gilbert, Alaska, Anchorage, Carmel , Calif, California, Sonal Singh Foster City, Calif, India, Foster City, Bingahlan New York City, Cordova , Alaska, Newark, Del, Atlanta, Sacramento, Gabby Cavazos Austin , Texas, Texas, Young Hilo, Hawaii

☆ We're hiking our price targets on Meta, Eli Lilly, and 3 other stocks on recent runs higher
▼ + stars: | 2024-07-09 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

AMZN YTD mountain Amazon YTD We begin with Amazon 's move, which has been fueled by strength in its three core businesses. GOOGL YTD mountain Alphabet YTD Alphabet has been gaining steam in recent months on similar cloud tailwinds but also improving sentiment around its AI capabilities. META YTD mountain Meta Platforms YTD Meta Platforms ' stock has fully recovered all of its first-quarter earnings losses. LLY YTD mountain Eli Lilly YTD We are also increasing our Eli Lilly price target – taking it to $1,000 per share from $850. PANW YTD mountain Palo Alto Networks YTD One more stock we're raising our price target for is Palo Alto Networks .

Persons: Eli Lilly, Eli Lilly YTD, There's, donanemab, We're, Jim Cramer's, Jim Cramer, Jim, Beata Zawrzel Organizations: Palo Alto Networks, Amazon, Jefferies, Facebook, Alto Networks, CNBC, Google, Nurphoto, Getty Locations: CIOs, United States, Indiana, Palo

☆ He lost 40 pounds on Mounjaro. Can he maintain it without the drug?
▼ + stars: | 2024-07-08 | by ( Gabe Ramirez | ) edition.cnn.com time to read: 1 min

How relevant is this ad to you? Video player was slow to load content Video content never loaded Ad froze or did not finish loading Video content did not start after ad Audio on ad was too loud Other issues

☆ Mounjaro leads to significantly more weight loss than Ozempic, study suggests
▼ + stars: | 2024-07-08 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

CNN —People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. But 82% of people taking tirzepatide reached this important clinical benchmark, compared with about 67% of those taking semaglutide. Average weight loss was also consistently higher among those taking tirzepatide over time. And by one year, average weight loss was nearly double for those taking tirzepatide — more than 11%, compared with about 6% for those taking semaglutide. According to the new study, individuals with type 2 diabetes had less significant weight loss than those without a diagnosis — but average weight loss was still greater among those taking tirzepatide.

Persons: tirzepatide, Eli Lilly, ”, Dr, Sanjay Gupta, CNN’s Brenda Goodman Organizations: CNN, US Food and Drug Administration, Novo Nordisk, semaglutide, FDA, CNN Health Locations: Truveta

☆ Eli Lilly shares have plenty room to run even after hitting a new high on Monday
▼ + stars: | 2024-07-08 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of the iPhone maker hit a new high after the opening. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Morgan Stanley, Wells, Eli Lilly, Joe Biden, Lilly's donanemab, Jim Cramer's Organizations: CNBC, Microsoft, Apple, Palo Alto Networks, Facebook, Palo, Bulls, Bears Locations: Palo, Palo Alto

☆ This ETF is trying to satisfy appetites for weight loss stocks
▼ + stars: | 2024-07-06 | by ( Ellie Stevens | ) www.cnbc.com time to read: 1 min

Tema ETFs has been capitalizing on the risk appetite for weight loss stocks. The firm's founder and CEO Maurits Pot thinks the winning weight loss trade isn't based on just hype. "We could see a world where the majority of the world's population takes a GLP-1, not just for weight loss, but for other diseases." His top holdings include Mounjaro manufacturer Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly is up 57% so far this year, while Novo Nordisk is up 38%.

Persons: Maurits Pot, Pot, Eli Lilly, Ozempic Organizations: Cardiometabolic, Novo Nordisk Locations: Tema, Novo

☆ Walgreens will close a ‘significant’ number of its 8,600 US locations
▼ + stars: | 2024-06-27 | by ( Jordan Valinsky | ) edition.cnn.com time to read: +3 min

New York CNN —Walgreens is set to close a substantial number of its roughly 8,600 locations across the United States as the company looks to reset the struggling pharmaceutical chain’s business. The company didn’t announce a specific number of store closures, but it said Thursday that it is planning “significant” closures of underperforming stores across America as part of a multiyear optimization program. The closures would focus on locations that aren’t profitable, too close to each other or stores struggling with theft, Wentworth told the Journal. Major drugstore chains, including CVS (CVS) and Rite Aid, have struggled in recent years because of declining profits from filling prescriptions. Wentworth told the Journal it’s losing money on filling those prescriptions.

Persons: Tim Wentworth, Wentworth, “, ” Wentworth, ” Neil Saunders, GlobalData, ” Saunders, drugstores, hasn’t, – CNN’s Nathaniel Meyersohn Organizations: New, New York CNN, Walgreens, Wall Street Journal, Journal, Walgreens ’, CVS, Rite, Amazon, Target, Rite Aid Locations: New York, United States, America, drugstores, VillageMD

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Best Buy : Jim said Best Buy's pullback in recent days has created a buying opportunity in the electronics retailer. Salesforce : The stock has in recent weeks clawed back some of its post-earnings plunge , even before Thursday's 6% surge. Wynn Resorts : Wynn is another stock in the portfolio that, it's become increasingly clear, trades based on its exposure to China. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Wall, Abbott, Johnson, We're, haven't, it's, Walt Disney, Estee Lauder, levered, Eli Lilly, Lilly, Morgan Stanley, Goldman Sachs, OpenAI, Jensen Huang, Nikesh Arora's, Stanley Black, Decker, TJX, We've, Wells, Charlie Scharf poaches, Wynn, Jim Cramer, Michael M Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Prime, Web, Broadcom, VMWare, Costco Wholesale, Costco, Coterra Energy, DuPont, Walt, Disney, Nvidia, Ford Motor, Ford, Blue, Motors, GE Healthcare, GE, Management, Honeywell, Linde, Microsoft, Palo Alto Networks, Procter & Gamble, Constellation Brands, Modelo, Corona, Fed, TJX, JPMorgan, Wynn Resorts, Wynn, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: China, Covid, Dover, Eaton, Palo Alto, U.S, Wells Fargo, Las Vegas

☆ DuPont draws suitors for its water unit, plus what's driving Eli Lilly's bounce
▼ + stars: | 2024-06-25 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer argued that the market's been too focused on the AI darling. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Eli Lilly, Novo Nordisk's Wegovy, Mounjaro, Ozempic, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, DuPont, Bloomberg, Novo Nordisk's, Club Locations: China, LLY

☆ In States That Won’t Pay for Obesity Drugs, ‘They May as Well Have Never Been Created’
▼ + stars: | 2024-06-25 | by ( Oliver Whang | ) www.nytimes.com time to read: +1 min

Joanna Bailey, a family physician and obesity specialist, doesn’t want to tell her patients that they can’t take Wegovy, but she has gotten used to it. Around a quarter of the people she sees in her small clinic in Wyoming County would benefit from the weight-loss medications known as GLP-1s, which also include Ozempic, Zepbound and Mounjaro, she says. The drugs have helped some of them lose 15 to 20 percent of their weight. But most people in the area she serves don’t have insurance that covers the cost, and virtually no one can afford sticker prices of $1,000 to $1,400 a month. “Even my richest patients can’t afford it,” Dr. Bailey said.

Persons: Joanna Bailey, ” Dr, Bailey Organizations: West Virginia —, West Virginia’s Public Employees Insurance Agency Locations: Wyoming, West Virginia

☆ The Promise of Weight-Loss Drugs
▼ + stars: | 2024-06-24 | by ( Dani Blum | ) www.nytimes.com time to read: +2 min

In the past two years, Ozempic has become a synonym for weight loss. Ozempic was weight loss; weight loss was Ozempic. Scientists believe the drugs are about to revolutionize several fields of medicine, such as cardiology and endocrinology. If these trials prove successful, the drugs may extend many lives by years, save billions in medical costs and divide public health into before-and-after epochs. These drugs, called GLP-1s (glucagon-like peptide 1 receptor agonists), mystify even the scientists who study them.

Persons: Ozempic, slimmed, we’ve, mystify Organizations: Food and Drug Administration

☆ Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
▼ + stars: | 2024-06-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The company said it plans to invest $6.8 billion in production this year, up from roughly $4 billion last year. Construction of the 1.4 million-square-foot facility has begun and is expected to be completed between 2027 and 2029, Novo Nordisk said. Twelve other production sites are located in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, according to a Novo Nordisk spokesperson. Around 35,000 U.S. patients on average start Wegovy each week today, up from roughly 27,000 in May, a Novo Nordisk spokesperson said in a statement.

Persons: Doug Langa, Clayton —, Langa, Eli Lilly Organizations: Novo Nordisk, Danish, Novo Nordisk's, Drug Administration Locations: Clayton , North Carolina, U.S, Novo, North Carolina, Clayton, Durham , North Carolina, West Lebanon , New Hampshire, Denmark, France, China, Japan, Algeria, Brazil, Iran, Russia

☆ Here's our first-quarter earnings report card for 32 stocks in the portfolio
▼ + stars: | 2024-06-21 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

Most of the earnings reports — 25 out of 32 portfolio names — were ranked as good or great by the Investing Club. Similar to prior quarters, we grouped company results into one of four categories. Meta Platforms : Sales, earnings and cash flow results all topped expectations . However, sales and earnings both outpaced expectations, as did return on tangible common equity, a key consideration when valuing banks. The company also raised its outlook for full-year earnings growth to 25% year-over-year from 20%.

Persons: we're, Dover, Eli Lilly, Blackwell, Abbott, —, Wall, We'll, Morgan Stanley, Nikesh, Stanley Black, Wells, Estee Lauder, Fabrizio Freda, Jim Cramer's, Jim Cramer, Jim, Hock Tan, Broadcom Lucas Jackson Organizations: Investing, Apple, Services, Broadcom, VMware, Coterra, DuPont, Microsoft, Nvidia, Wynn Resorts, Super, Abbott Labs, Web Services, Constellation Brands, Constellation, Ford, Ford Pro, Wall Street, Alto Networks, Procter & Gamble, TJX, GE Healthcare, Honeywell, Linde, Jim Cramer's Charitable, CNBC Locations: Dover, China, Eaton, Las Vegas, China's Macao, billings, Wells Fargo, —

☆ 10 things to watch in the stock market Thursday including the latest call on Nvidia
▼ + stars: | 2024-06-20 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Stifel raised its price target on Nvidia to $165 a share from $114, implying nearly 22% upside from Tuesday's close. Keybanc raised its price target on Club holding Meta Platforms to $540 a share from $475, citing a "meaningful uptick" in ad prices. Tesla price target lowered to $227 a share from $293 at RBC Capital, but analysts maintained their outperform rating on the electric vehicle maker's stock. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stifel, Olive Garden, Piper Sandler, Keefe, Eli Lilly, Tesla, Uber, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Nvidia, Microsoft, Darden, LongHorn, Honeywell, CAES, Holdings, Accenture, Citigroup, Citi Services, Citi . Club, RBC Capital, RBC, Jim Cramer's Charitable, CNBC Locations: U.S

☆ Nvidia and these other megacap stocks are extremely overbought and could be due for a near-term pullback
▼ + stars: | 2024-06-19 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Now that megacap stocks have lifted the S & P 500 and Nasdaq Composite indexes to all-time highs, some stocks in the group have risen so high, so fast they may actually be due for a pullback. Pharmaceutical developer Eli Lilly , maker of Mounjaro for Type 2 diabetes and Zepbound for obesity, is higher by 53% this year. By contrast, the S & P 500 is up 15% this year, through Tuesday's close. Eli Lilly is also now extremely overbought, Bespoke said, after benefiting from increased demand for its weight loss and diabetes drugs. Other stocks considered extremely overbought are Nvidia, Apple and Microsoft, which have traded more than 33%, 17% and 7%, respectively, above their 50-day moving averages.

Persons: Eli Lilly, Lilly Organizations: Nasdaq, Nvidia, Broadcom, Pharmaceutical, Investment, Microsoft, Apple Locations: Tuesday's, Indiana

☆ How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
▼ + stars: | 2024-06-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Skyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new heights over the last year. But the drugmaker has much more work it wants to do with that hard-won success, outgoing Chief Financial Officer Anat Ashkenazi told CNBC. Ashkenazi took over as CFO at Eli Lilly in 2021 after roughly two decades with the pharmaceutical giant. Her tenure hasn't come without challenges: Eli Lilly and rival Novo Nordisk have both struggled to manufacture enough supply of their treatments to meet unprecedented demand, causing nationwide shortages of those drugs. Eli Lilly does not expect to match the pace of demand this year and maybe not even in 2025, Ashkenazi said at a conference in March.

Persons: Eli Lilly, Anat Ashkenazi, Eli, Zepbound, Ashkenazi, Eli Lilly's Organizations: CNBC, Novo Nordisk

Search resuls for: "Mounjaro"

25 mentions found